Science is harvesting more and more information about the human population, and individual patients specifically. Medicine is understanding the roles of genomics and the environment in a patient’s medical history. Yet translating this data to practice has proved difficult. The fundamental question for a physician is still: will this treatment work for my patient?
How can the wealth of medical information be factored into patient medical records and into everyday care — more quickly, more usefully and more completely?
How can insights into individual patients — gleaned from in vitro and in vivo diagnostic tests — allow us to zero in on targeted therapies?
Meet the Challenge Team
The Challenge Team Members are leaders in their fields and reflect multi-disciplinary, passionate and thoughtful perspectives for the Challenge they represent.
Challenge Team members participate in the discussion held by the Great Challenges community, and will be creating responses to questions submitted by the community on the discussion tab.
Prior to his tenure with Clarient, Dr. Pellini served as Vice President, Life Sciences at Safeguard Scientifics, Inc. where he leveraged his business and medical expertise to explore new market opportunities and to support Safeguard’s partner companies. Prior to Safeguard, he was Executive Vice President and Chief Operating Officer at Lakewood Pathology Associates, a national molecular and pathology services company, which was acquired by Water Street Healthcare Partners in 2006. Prior to that, Dr. Pellini was an Entrepreneur-in-Residence at BioAdvance, where he was responsible for reviewing and evaluating early-stage life science companies. He also served as President and Chief Executive Officer of Genomics Collaborative, Inc., a Boston-based biotech firm that was acquired by SeraCare Life Sciences, Inc. in 2004.
Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College of Thomas Jefferson University. Dr. Pellini serves as a member the Boston College Technology Council, the Executive Committee of the Jefferson Medical College Alumni Association, and the Board of Trustees for the Coriell Institute of Medical Research.
As President and Chief Medical Officer of InformedDNA, she currently leads a national team of board-certified genetics specialists providing genetic counseling services by telephone and the web, and providing expert consultative services to health plans, healthcare and provider organizations, laboratories and pharmaceutical companies.
As Professor of Genetics at the USF Morsani College of Medicine, Dr. Sutphen has led a translational research program focused on personalized medicine, with funding from the National Institutes of Health, the Department of Defense and the American Cancer Society, among others. She has received numerous clinical awards and honors including "America's Top Doctors" and "Best Doctors in America” and has authored more than 50 peer-reviewed scientific articles as well as the recently published Johns Hopkins University Press book Confronting Hereditary Breast and Ovarian Cancer: Identify Your Risk, Understand Your Options, Change Your Destiny.
Challenge Team Perspectives
We selected 10 questions out of the many submitted by our Great Challenges Community, to be addressed by each of our Team members.
See their responses and perspectives, below.
Question 1What are the biggest ethical issues posed by personalized medicine – e.g., keeping an individual’s genetic information confidential and guarding against genetic discrimination – and what steps are needed to protect patients from such harms?
Select a Question to View The Challenge Team's Responses
The following questions were submitted by the TEDMED Community and selected for further discussion. The Team Members have weighed in on each, select below to see their responses: